STK11 mutation status is associated with decreased survival in meningiomas

Abstract

Background Emerging evidence suggests that STK11 mutations may influence clinical outcome and response to immunotherapy in cancer. Materials and methods Next-generation targeted sequencing of STK11 mutation status in a large cohort of 188 meningiomas. Results STK11 loss-of-function mutations were identified in 3.7% of meningiomas. STK11 mutations were found in both low- and high-grade lesions and samples from primary and recurrent disease. There was a 2.8-fold increased risk of death for patients whose meningioma harbored an STK11 mutation, after controlling for lesion grade and occurrence status. The median overall survival for patients with STK11-mutated meningiomas was 4.4 years compared with 16.8 years. Conclusion These data identify recurrent STK11 mutations in a subset of meningiomas. Genotyping of STK11 is encouraged for meningioma patients undergoing immunotherapy-based therapy.